Our Company
THE LEADING RNAi THERAPEUTICS COMPANY
Alnylam’s pioneering science has yielded the critical breakthroughs and innovations that have made RNA interference (RNAi)-based medicines a reality. We ushered in the first phase of the RNAi RevolutionTM by developing the first five approved RNAi therapeutics. Now, we’re pioneering what’s next, working to bring RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and which impact millions of people around the world.
OUR RESEARCH IS CHANGING THE WAY DISEASES ARE TREATED MEDICINES
Our Science
OUR PIPELINE
Our robust pipeline of investigational RNAi therapeutics is currently focused on diseases with high unmet medical need, including transthyretin amyloidosis, rare diseases, cardiovascular diseases, metabolic diseases, and neurological diseases. Additionally, we will always follow the science and are continually looking for new disease targets that may benefit from our RNAi technology.
Transthyretin amyloidosis (ATTR)
Rare Diseases
Cardiovascular
Diseases
Metabolic Diseases
Neurologic
Diseases
Careers
JOIN OUR TEAM
We are growing quickly and hiring across North America, Europe, Asia, and Latin America for a wide variety of roles. We’re seeking smart, passionate, “change the world” kind of people who are ready to say, “challenge accepted” to our mission.